Relmada Therapeutics

Dr. Ottavio Vitolo Appointed Executive Clinical Advisor at Relmada Therapeutics See more here

Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors See more here

Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder See more here

Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone See more here

Relmada Therapeutics Announces Issuance of Key U.S. Patent Covering d-Methadone, an NMDA receptor Antagonist, for the Treatment of Depression and Other Psychiatric Symptoms See more here

Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression See more here

Relmada Therapeutics Announces Results of In Vivo Study Showing d-Methadone has Antidepressant-like Effects See more here

Relmada Therapeutics Announces Publication of Full Results from Phase I Study Showing Treatment with d-Methadone to be Safe and Well Tolerated See more here

Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine Read more here

Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase One Study of Novel NMDA Receptor Antagonist d-Methadone Read more here